Bad Brains, Bad Outcomes

Department of Internal Medicine, University of Michigan, Ann Arbor, MI Department of Internal Medicine, University of Michigan; and VA Center for Clinical Management Research, HSR&D Center of Innovation, Ann Arbor, MI *See also p. 843. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U.S. government. This editorial discusses the use of dexmedetomidine and antipyschotics for treatment of delirium, which is not a U.S. Food and Drug Administration-approved indication for use. Supported, in part, by grants K08 GM115859 from the National Institutes of Health (to Dr. Prescott). Dr. Prescott’s institution received funding from the National Institutes of Health (NIH)/National Institute of General Medical Sciences, and she received support for article research from the NIH. She disclosed that she is a Department of Veterans Affairs (VA) employee, and the views in this article do not necessarily represent the position or policy of the U.S. government or the VA. She previously served on an advisory board for a Bristol-Meyers-Squibb study (unpaid). Dr. Hensley has disclosed that he does not have any potential conflicts of interest.